Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GYRE
GYRE THERAPEUTICS, INC.
NASDAQ
$6.59
▼ DOWN 1.35% (-0.09)

KEY STATISTICS

Market Cap$734.71 M
52w High$9.42
52w Low$5.44
Dividend Yield642.31%
FrequencyQuarterly
P/E94.14
Volume43.16K
Shares Out.111.49M

COMPANY

LEADERSHIP

Ying Luo
CHIEF EXECUTIVE
Ying Luo

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 12, 2006
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
625

PRICE TARGET

Target High$18.00
Target Low$16.00
Target Median$17.00
Target Consensus$17.00

UPCOMING EARNINGS

DateNov 6, 2026
DayFriday
Rev. Est.$28.40M
NOV
6
FRI

SPLIT RECORD

DATETYPERATIO
2023-10-31Reverse1:15
2017-02-13Reverse1:15
2015-08-21Reverse1:7

PRICE

$6.59 ▼ DOWN 1.35% (−$0.09)
OVERLAYS
$6.54$6.57$6.60$6.639:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM6.59

About Gyre Therapeutics, Inc.

https://www.gyretx.com ↗

Gyre Therapeutics develops anti-inflammatory and anti-fibrotic drugs like Pirfenidone for organ fibrosis, with several candidates in Phase 1-3 trials targeting lung, liver, and other fibrotic diseases.

INDUSTRY

Biotechnology

A PRODUCT GYRE THERAPEUTICS, INC. IS KNOWN FOR

Hydronidone (F351)
Hydronidone (F351)

Hydronidone, a late-stage small-molecule drug candidate for liver fibrosis and MASH, is Gyre Therapeutics' primary focus, with positive Phase 3 results in treating hepatitis B-associated fibrosis.

COMPETITORS

COMPETITOR
GALT COMPARE
MDGL COMPARE
VKTX COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q1-2026Q2-2026
Pharmaceutical Products— — — $29.1M
Product$22.1M $26.8M ▲$22.5M ▼—

ETFS HOLDING THIS STOCK

ETFS HOLDING
50
LISTED HERE
12
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.4M
IWM
0.00% · 389.2K
SCHA
0.00% · 99.0K
EES
0.02% · 19.5K
XRSU.L
0.00% · 17.0K
R2US.L
0.00% · 14.8K
DFMC
0.00% · 9.9K
RSSL
0.00% · 8.7K
AVSC
0.00% · 1.9K
KBFR
0.05% · 884
URTY
0.00% · 746
SC0K.DE
0.00% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
8.05%
HOLDERS
75
TOP 12 OF 75 · RANKED BY POSITION SIZE
Sc China Holding Ltd
3.8M sh · $24.71M
Vanguard Group Inc
1.2M sh · $8.48M
Blackrock, Inc.
993.9K sh · $6.55M
Octagon Capital Advisors LP
954.4K sh · $6.29M
Geode Capital Management, LLC
533.0K sh · $3.51M
Blackrock Inc.
499.5K sh · $5.96M
State Street Corp
245.4K sh · $1.62M
Sixth Street Partners Management Company, L.P.
184.3K sh · $1.21M
Charles Schwab Investment Management Inc
184.3K sh · $1.21M
Sbi Securities Co., Ltd.
170.8K sh · $1.19M
Northern Trust Corp
169.5K sh · $1.12M
Goldman Sachs Group Inc
86.2K sh · $568.29K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Kirkby Maxwell
Purchase · 40.0K shares
2026-08-03
★
Weston Claire
— · —
2026-08-01
★
DIRECTOR
Weston Claire
Purchase · 40.0K shares
2026-08-03
★
Kirkby Maxwell
— · —
2026-08-01

SECTORS PEERS

PEERPRICE
ERAS$18.03COMPARE
IOVA$8.01COMPARE
MBX$63.00COMPARE
AVBP$30.17COMPARE
MGTX$13.82COMPARE
MLTX$14.99COMPARE
CTMX$3.21COMPARE
KROS$11.03COMPARE